Eintrag weiter verarbeiten
Verfügbar über Online-Ressource

Takotsubo syndrome and cardiac implantable electronic device therapy

Gespeichert in:

Veröffentlicht in: Scientific reports 9(2019) Artikel-Nummer 16559, 6 Seiten
Personen und Körperschaften: El-Battrawy, Ibrahim (VerfasserIn), Erath-Honold, Julia (VerfasserIn), Lang, Siegfried (VerfasserIn), Ansari, Uzair (VerfasserIn), Behnes, Michael (VerfasserIn), Gietzen, Thorsten (VerfasserIn), Zhou, Xiao-Bo (VerfasserIn), Borggrefe, Martin (VerfasserIn), Akın, Ibrahim (VerfasserIn)
Titel: Takotsubo syndrome and cardiac implantable electronic device therapy/ Ibrahim El-Battrawy, Julia W. Erath, Siegfried Lang, Uzair Ansari, Michael Behnes, Thorsten Gietzen, Xiaobo Zhou, Martin Borggrefe & Ibrahim Akin
Format: E-Book-Kapitel
Sprache: Englisch
veröffentlicht:
12 November 2019
Gesamtaufnahme: : Scientific reports, 9(2019) Artikel-Nummer 16559, 6 Seiten
, volume:9
Quelle: Verbunddaten SWB
Lizenzfreie Online-Ressourcen
Details
Zusammenfassung: Recent studies have reported that takotsubo syndrome (TTS) patients are suffering from life-threatening arrhythmias. The aim of our study was to understand the short and long-term usefulness of cardiac implantable electronic devices in TTS patients.We constituted a collective of 142 patients in a bi-centric study diagnosed with TTS between 2003 and 2017. The patient groups, divided according to the treatment with (n = 9, 6.3%) or without cardiac devices (n = 133, 93.7%), were followed-up to determine the importance of devices and its complications. One patient was treated with a permanent pacemaker, five patients with a wearable cardioverter defibrillator, two patients with a subcutaneous defibrillator and one patient with a transvenous defibrillator. Regular device check-up was documented in all patients, presenting an ongoing high-degree AV-block. Neither device complications nor life-threatening tachyarrhythmias were documented after acute TTS event. However, patients comprising the device group suffered significantly more often from a highly reduced EF (30 ± 7.7% versus 39.1 ± 9.7%; p < 0.05), cardiogenic shock with use of inotropic agents (66.6% versus 16.6%; p < 0.05) and cardiopulmonary resuscitation (44.4% versus 5.3%; p < 0.05). Our data confirm the usefulness of pacemaker in TTS patients. However, the cardioverter defibrillator including wearable cardioverter defibrillator may not be recommended.
Beschreibung: Gesehen am 02.03.2020
Umfang: 6
ISSN: 2045-2322
DOI: 10.1038/s41598-019-52929-5